Cargando…

Resistance to the CHK1 inhibitor prexasertib involves functionally distinct CHK1 activities in BRCA wild-type ovarian cancer

High grade serous ovarian cancer (HGSOC) is a fatal gynecologic malignancy in the U.S. with limited treatment options. New therapeutic strategies include targeting of the cell cycle checkpoints, e.g., ATR and CHK1. We recently reported a promising clinical activity of the CHK1 inhibitor (CHK1i) prex...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nair, Jayakumar, Huang, Tzu-Ting, Murai, Junko, Haynes, Brittany, Steeg, Patricia S., Pommier, Yves, Lee, Jung-Min
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2020
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7426265/ https://www.ncbi.nlm.nih.gov/pubmed/32647134 http://dx.doi.org/10.1038/s41388-020-1383-4

Ejemplares similares

Prexasertib, a Chk1/Chk2 inhibitor, increases the effectiveness of conventional therapy in B-/T- cell progenitor acute lymphoblastic leukemia
por: Rorà, Andrea Ghelli Luserna Di, et al.
Publicado: (2016)

EGFR signaling promotes resistance to CHK1 inhibitor prexasertib in triple negative breast cancer
por: Lee, Kevin J., et al.
Publicado: (2020)

Chk1, Chk2, is the amplifier on?
por: Dove, Alan W.
Publicado: (2001)

A pan-cancer transcriptome analysis identifies replication fork and innate immunity genes as modifiers of response to the CHK1 inhibitor prexasertib
por: Blosser, Wayne D., et al.
Publicado: (2020)

Clinical outcomes of prexasertib monotherapy in recurrent BRCA wild-type high-grade serous ovarian cancer involve innate and adaptive immune responses
por: Lampert, Erika J, et al.
Publicado: (2020)

Regulation of Chk1
por: Tapia-Alveal, Claudia, et al.
Publicado: (2009)

Tumour growth environment modulates Chk1 signalling pathways and Chk1 inhibitor sensitivity
por: Massey, Andrew J.
Publicado: (2016)

SLFN11 promotes CDT1 degradation by CUL4 in response to replicative DNA damage, while its absence leads to synthetic lethality with ATR/CHK1 inhibitors
por: Jo, Ukhyun, et al.
Publicado: (2021)

Keeping RelApse in Chk: molecular mechanisms of Chk1 inhibitor resistance in lymphoma
por: Black, Elizabeth M., et al.
Publicado: (2022)

Clinical and functional significance of CHK1-S, an alternatively spliced isoform of the CHK1 gene, in hepatocellular carcinoma
por: Hu, Guanghui, et al.
Publicado: (2020)

Ubiquitination of the DNA-damage checkpoint kinase CHK1 by TRAF4 is required for CHK1 activation
por: Yu, Xinfang, et al.
Publicado: (2020)

Prexasertib, a cell cycle checkpoint kinases 1 and 2 inhibitor, increases in vitro toxicity of PARP inhibition by preventing Rad51 foci formation in BRCA wild type high-grade serous ovarian cancer
por: Brill, Ethan, et al.
Publicado: (2017)

Trial Watch: Targeting ATM–CHK2 and ATR–CHK1 pathways for anticancer therapy
por: Manic, Gwenola, et al.
Publicado: (2015)

Chk1 suppressed cell death
por: Meuth, Mark
Publicado: (2010)

Checkmate to CHK1 in T-cell ALL?
por: Sarmento, Leonor M., et al.
Publicado: (2015)

BRD7 suppresses tumor chemosensitivity to CHK1 inhibitors by inhibiting USP1-mediated deubiquitination of CHK1
por: Li, Lemin, et al.
Publicado: (2023)

Chk1 C-terminal regulatory phosphorylation mediates checkpoint activation via derepression of Chk1 catalytic activity
por: Walker, M, et al.
Publicado: (2009)

A novel Chk1-binding peptide that enhances genotoxic sensitivity through the cellular redistribution of nuclear Chk1
por: Kim, Kwang Seok, et al.
Publicado: (2016)

Dominant mutations in CHK1 cause pronuclear fusion failure and zygote arrest that can be rescued by CHK1 inhibitor
por: Zhang, Honghui, et al.
Publicado: (2021)

The Role of Wild-Type p53 in Cisplatin-Induced Chk2 Phosphorylation and the Inhibition of Platinum Resistance with a Chk2 Inhibitor
por: Liang, Xiaobing, et al.
Publicado: (2011)

Olaparib Combined with an ATR or Chk1 Inhibitor as a Treatment Strategy for Acquired Olaparib-Resistant BRCA1 Mutant Ovarian Cells
por: Burgess, Brian T., et al.
Publicado: (2020)

Targeting Chk1 in the replicative stress response
por: Dai, Yun, et al.
Publicado: (2010)

Combinations of ATR, Chk1 and Wee1 Inhibitors with Olaparib Are Active in Olaparib Resistant Brca1 Proficient and Deficient Murine Ovarian Cells
por: Chiappa, Michela, et al.
Publicado: (2022)

γH2AX and Chk1 phosphorylation as predictive pharmacodynamic biomarkers of Chk1 inhibitor-chemotherapy combination treatments
por: Rawlinson, Rebecca, et al.
Publicado: (2014)

Overexpression of TopBP1, a canonical ATR/Chk1 activator, paradoxically hinders ATR/Chk1 activation in cancer
por: Liu, Kang, et al.
Publicado: (2021)

Regulation, targets and functions of CHK
por: Zhu, Shudong, et al.
Publicado: (2022)

DNA-PKcs activates the Chk2–Brca1 pathway during mitosis to ensure chromosomal stability
por: Shang, Z, et al.
Publicado: (2014)

Exploring the Synergy between PARP and CHK1 Inhibition in Matched BRCA2 Mutant and Corrected Cells
por: Smith, Hannah L, et al.
Publicado: (2020)

Analysis of the ATR-Chk1 and ATM-Chk2 pathways in male breast cancer revealed the prognostic significance of ATR expression
por: Di Benedetto, Anna, et al.
Publicado: (2017)

Chk1 Haploinsufficiency Results in Anemia and Defective Erythropoiesis
por: Boles, Nathan C., et al.
Publicado: (2010)

Targeting the ATR-CHK1 Axis in Cancer Therapy
por: Rundle, Stuart, et al.
Publicado: (2017)

The Influence of PARP, ATR, CHK1 Inhibitors on Premature Mitotic Entry and Genomic Instability in High-Grade Serous BRCA(MUT) and BRCA(WT) Ovarian Cancer Cells
por: Gralewska, Patrycja, et al.
Publicado: (2022)

Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells
por: Kim, Marianne K, et al.
Publicado: (2015)

Prexasertib, a cell cycle checkpoint kinase 1 and 2 inhibitor, in BRCA wild-type recurrent high-grade serous ovarian cancer: a first in class, proof-of-concept, single arm phase 2 study
por: Lee, Jung-Min, et al.
Publicado: (2018)

Analysis of CHK2 in vulval neoplasia
por: Reddy, A, et al.
Publicado: (2002)

Chk-mate on resistance to kinase inhibitors
por: Shapiro, Paul
Publicado: (2018)

Editorial: Regulation and dysfunction of CSK and CHK
por: Zhu, Shudong, et al.
Publicado: (2023)

Activation of mammalian Chk1 during DNA replication arrest: a role for Chk1 in the intra-S phase checkpoint monitoring replication origin firing
por: Feijoo, Carmen, et al.
Publicado: (2001)

CTP sensing and Mec1(ATR)-Rad53(CHK1/CHK2) mediate a two-layered response to inhibition of glutamine metabolism
por: Ajazi, Arta, et al.
Publicado: (2022)

Panobinostat Enhances Cytarabine and Daunorubicin Sensitivities in AML Cells through Suppressing the Expression of BRCA1, CHK1, and Rad51
por: Xie, Chengzhi, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_ihfl42npkp2lba0um4fhtidl8v